Background: Angiogenesis is an essential factor for progression and metastases in solid tumors. It has been reported that several angiogenic factors playa role in the regulation of angiogenesis. Vascular endothelial growth factor (VEGF) is one of the most important molecules in angiogenesis. We investigated expressions of VEGF in a series of lung carcinomas with regard to clinicopathological factors. Method: VEGF expression was investigated by use of immunohistochemical studies and Northern blot analysis, using 155 primary and 26 metastatic lung carcinomas for the immunohistochemical studies and 10 primary and two metastatic lung carcinomas for the Northern blot analysis. All lesions were resected at surgery. Results: The frequencies for positive VEGFexpression were 64 of 74 (86.5%) adenocarcinomas, 38 of 67 (56.7%) squamous cell carcinomas, four of four (100%) large cell carcinomas, two of three (66.7%) adenosquamous carcinomas and one of five (20%) small-cell carcinomas, the degree of positivity generally being greater in well differentiated tumors. The majority of metastatic foci from adenocarcinomas and squamous cell carcinomas at other sites were also positive (76.5 and 66.70/0, respectively). VEGF expression did not correlate with clinicopathological factors such as tumor size or pathological stage, but pathological stage I adenocarcinoma cases positive for VEGF demonstrated a shorter disease-free period when followed up for 48 months than those cases expressing VEGF negatively. Conclusions: The results indicated that VEGF expression was frequently detected in non-small-cell lung cancers and suggested that VEGF might relate to the disease-free period of the patients with early adenocarcinomas.
INTRODUCTION
It is well accepted that carcinogenesis is a multistep process involving various gene alterations and expression of various factors and their receptors (1-3). The genetic and molecular mechanisms that control angiogenesis have yet to be fully elucidated, but the vascular endothelial growth factor (VEGF) is known to be important for vessel development (1-5). It is now clear that angiogenesis can be positively regulated by several angiogenic molecules (4, 5) which are essential for the late stage of carcinogenesis and especially the progression phase (1,2). VEGF acts directly on endothelial cells through specific receptors (6) (7) (8) (9) (10) (11) and it has been demonstrated that VEGF mRNA and protein are expressed in colon cancer cell lines (12) . Further, recent studies have shown a positive correlation between VEGF expression and high metastatic potential of breast (13) (14) (15) , prostate (16) , colon (17, 18) and other cancers (19) (20) (21) (22) . These results indicate that VEGF expression might be an indicator of a poor prognosis but this is still controversial and more studies of different human neoplasms are needed. In the respiratory system, it has been reported that VEGF overexpression can be detected in endothelial cells under hypoxic conditions and in ischemic regions (23) . With regard to lung cancers, it has been reported that VEGF mRNAs in secretory forms (VEGFI21 and VEGFI65) are predominantly transcribed in both resected lung cancer tissues and in human lung cancer cell lines and suggested that VEGF121 expression, which is efficiently secreted and promotes mitogenesis of endothelial cells, in particular might be a prognostic markerfor lungcancerpatients afteroperation (24) .In thepresentinvestigation, we studied the frequency of VEGFexpression in resected lesions in relation to clinicopathological factors.
MATERIALS AND METHODS

PATIENTS AND TISSUE SAMPLES
Paraffin-embedded tumor specimens taken from lung cancer patients who underwent operations at the Third Department of Surgery, Nara Medical University, fromJanuary 1993 to December 1995 were used. The histological types, numbers, genderof patients and pathological stages of the primary lung and metastatic cancers are shown in Table 1 . The histology and pathological stage were classified according to General Rules for Clinical and Pathological Recording of Lung Cancers (25) . The metastatic lung tumors were from nine rectal adenocarcinomas, four colon adenocarcinomas, three osteosarcomas, two squamous cell carcinomas of the uterus, two transitional cell carcinomas of the urinary bladder, two breast adenocarcinomas, one renalcellcarcinoma, onelaryngeal squamous cell carcinoma, one thyroid adenocarcinoma and one hepatocellular carcinoma. Tworepresentative serial 5 urn sections from each case were made for the investigations from paraffin-embedded samples. One section wasstainedwithhematoxylin andeosin forhistological examination and the other section was stained with VEGF for further immunohistochemical investigation. In addition to these, fresh tissues from five lung adenocarcinomas, three squamous cell carcinomas and two adenosquamous carcinomas, in addition to two metastatic colonadenocarcinomas and therespective non-cancerous tissues adjacent to tumor areas were frozen immediately after surgical removal in liquid nitrogen and stored at -80°C for subsequent Northern blot analysis.
IMMUNOHISTOCHEMICAL STUDIES
Deparaffmized sections were incubated with normal horse serum dilutedwith'Iris-bufferedsaline(TBS)at I:50 for 30 min and then the rabbitpolyclonal anti-VEGF antibody (SantaCruzBiotechnology,SantaCruz,CA, USA) at 1:200in TBS containing 2% bovine serum albumin for 2 h at room temperature. Visualization of bindingwasperformed withan LSAB 2 kit (DAKOJapan,Kyoto, Japan) and 0.03% 3,3-diaminobenzidine tetrahydrochloride in TBS for 5 min. We defmed it as immunohistochemically positive when the cytosolic area of the cells diffusely exhibited the anti-VEGF binding. In any of the other cases, the results were treatedas negative. Expression levelsof VEGF werecharacterized as follows: not stained at all, negative (A-); less than 50% of the tumor tissue stained, slightly positive(A±); over 50% of the tumor tissue stained, positive (+); and almostall the tumor tissuestained, strongly positive (++) . As the negativecontrol, rabbitnon-immune serum was used instead of the primary antibody.
PREPARATION OF cDNA PROBES
It has been reported that the rat form 3 VEGF splicing variant is 100% homologous to human VEGF exon 6 (Yakovlev AG, Faden AD, uploaded with RNVEGF3H as an identification number on EMBLNucleotide Sequence DataBase). A 0.432kilobase fragment of its cDNA sequence was therefore obtained by RT-PCR amplification and used as a probe. Total RNAs were derived from 4-hydroxyaminoquinoline l-oxide-induced osteosarcomas (26) usingan RNAzol kit (TEL-TEST, Friendwood, TX, USA), reverse transcribed to cDNAwithan oligodeoxythymidylic acidprimerand thenpoly-Aselected. The cDNA obtained was subjected to PCR to amplify the0.432kilobase fragment usinga protocol modified from that recommended for the GeneAmp DNA Amplification Reagent Kit (Perkin-Elmer Cetus, Norwalk, CT, USA) with 20 ul of PCR mixture containing 0.2mM of each dNTP, 0.25mM of eachprimer and 0.5 units of Taq polymerase (pharmacia Biotech, Uppsala, Sweden) in PCR buffer (50mMKCI-10 mMTris, pH 8.~1.5 mM MgCI2-D.01 % gelatin). The primer sequences were 5-GGT GAA GTI CAT GGACGTCT-3 fortheforward primerand5-GTCTGC GGA TCT TGG ACA A-3 for the reverse primer. The PCR conditions were I min at 94°C for preheating; 30 cycles of 30 s of denaturation at 94°C, 45 s of annealing at 57°C, 90 s of extension at 72°C; and 8 min post-extension at 72"C, The amplified segments were verified by electrophoresis in I% agarose gels with ethidium bromide and extracted witha Wizard peR PrepsDNA Purification System(Promega, Madison, WI, USA). Directsequencing wasthen carried out to confirm the human VEGF cDNA sequence and the amplified cDNA was used as a probe. NSCLC, non-small-cell lung carcinoma; SCLC, small-cell lung carcinoma; Ad, adenocarcinoma; Sq, squamous cell carcinoma; Large, large cell carcinoma; Adsq, adenosquamous carcinoma. *Three osteosarcomas, two transitional cell carcinomas and one clear cell carcinoma. 
NORTHERN BLOT ANALYSIS
Total RNA was extracted from cancerous and non-cancerous lung tissues using an ISOGENE kit (Nippon Gene, Toyama, Japan) and 20 !lg aliquots were electrophoresed in 1% agarose-formaldehyde gels, transferred to Biodyne A nylon membranes (Pall Biosupport, East Hills, NY, USA) and hybridized with I x 10 6 c.p.m./ml of the 32P-radiolabeled cDNA probe prepared using a DNA Labeling Kit (d-CTP) (Pharmacia Biotech) in a mixture of 50% formamide, 5x standard saline citrate (SSC), 0.1 M phosphate buffer (pH 7.4), 5x Denhardt's solution, 0.1% sodium dodecyl sulfate (SDS), 5 mM EDTA and 100 !lg/ml salmon testis DNA at 45°C overnight. Blots were washed in 2x SSC and 0.1% SDS at room temperature for 15 min and twice in 2x SSC and 0.1 % SDS at 55°C for 15 min ; then overnight they were exposed to Hyper-film-MP (Amersham Japan, Tokyo, Japan) using an intensifying screen, at -80°C. After the exposure, the Northern blots were reprobed with a glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA probe to confirm that similar amounts of RNA were loaded and transferred from each sample.
cell carcinomas, four large cell carcinomas and three adenosquamous carcinomas were examined, along with five small-cell lung cancers (SCLCs) . VEGF expression of the NSCLC was found in 73.0% with no differences in frequency among the histological types, while only one of the SCLC was positive (20.0%). All positive cases were (+) or (++). The cases of (A±) were classified as being negative.
VEGF EXPRESSION AND DIFFERENTIATION/PATHOLOGICAL STAGE
Data for VEGF expression relative to differentiation and pathological stage of primary lung adenocarcinomas and squamous cell carcinomas are shown in Table 3 . Well ( Fig. 1) and moderately differentiated adenocarcinomas in addition to well differentiated squamous cell carcinomas (Fig. 2 ) demonstrated a higher degree of expression than their poorly differentiated counterparts. However, the frequencies of VEGF did not differ significantly with the pathological stage. 
STATISTICAL ANALYSES
VEGF expression in relation to pathological stage, histological type and cancer cell differentiation was analyzed for significance using Student's r-test. Disease-free periods were calculated by the Kaplan-Meier method and the data were evaluated with the log rank test.
RESULTS
VEGF EXPRESSION AND PATHOLOGICAL FINDINGS
Data for VEGF expression in comparison with pathological stage of primary lung cancers are shown in .... ,.. , , .
.~. Percentage values are given in parentheses.
VEGF EXPRESSION IN METASTATIC LUNG TUMORS
The majority of the metastatic foci from adenocarcinomas showed positivestaining (Fig. 3 ) and the frequencywas 13out of 17 (76.5%) cases. Negativecases were two rectal adenocarcinomas, one colon adenocarcinoma and one thyroid adenocarcinoma. For squamous cell carcinomas, the frequency was two out of three (66.7%) cases. Metastatic foci from transitional cell carcinomasof the urinary bladderandclear cellcarcinomasof the kidney provednegative, while threecases of metastaticosteosarcomas were positive where present, the staining intensity of the metastatic tumors being (+) or (++) positive appearances.
NORTHERN BLOT ANALYSIS
In recent cases,pairedsamples of tumor and non-cancerous lung tissue from 12 patients were subjected to Northern blot analysis, using cDNA probe for VEGF. Representative results of Northern blot analysis are shown in Fig. 4 . VEGF mRNA was expressed in five primary adenocarcinomas, three squamous cell carcinomas, two adenosquamous carcinomas and two metastatic carcinomas from the colon compared with non-cancerous lung tissue in each. All cases which expressed VEGF mRNA in Northern blotanalysiswerestained with anti-VEGF antibodypositivelyor strongly positively, respectively.
VEGF EXPRESSION AND THE DISEASE-FREE PERIOD FOR PATHOLOGICAL STAGE I CASES WITH NSCLC
Results for the analysis of data for VEGF expression and the disease-free period after 48 months follow-up for pathological stage I cases are shown in Fig. 5 . With the adenocarcinomas, the disease-free period was shorter for VEGF positive than for negative cases (p < 0.05). However, with the squamous cell carcinomas, no difference between the VEGF positive and negativecases was found.
DISCUSSION VEGF was first detected as an important angiogenic factor inducing microvascular hyperpermeability (27, 28) and extra-.
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' .,". associated with a reduction in VEGF acnvrty. The present findings of a high frequency of VEGF expression might therefore suggest a background of ras mutations, although generally low mutation frequency of this oncogene in NSCLCs could not account for all cases (31, 32) . Up-regulation of VEGF was detected in almost all well differentiated carcinomas in the present series but was unexpectedly less common in poorly differentiated carcinomas. VEGF expression did not correlate with the pathological stage in our cases, but follow-up of stage I adenocarcinoma patients for 48 months after operation revealed a significantly longer disease-free period for patients with negative compared with those with positive tumors. Our results therefore are in line with the report of Ohta et al. (24) that survival of VEGF121 mRNA high-expressing cases is less than that for the low-expressing group of stage I primary lung cancer patients.
Recently, the potential importance of VEGF for diagnosis and treatment has been emphasized. Salven as an endothelial cell mitogen (8, 29) . In recent studies, it has been shown that various malignant tumors exhibit up-regulation of VEGF expression (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) and that this is associated with a high probability of metastasis and a resultant poor prognosis (12, 13) . In the present study, VEGF expression was investigated in a large series of resected primary and metastatic lung carcinomas. NSCLCs demonstrated greater positivity than SCLCs. Our results also indicate that overexpression of VEGF is more frequent in primary adenocarcinomas than in squamous cell carcinomas. Ohta et al. (24) reported that there was no positive correlation between expression of the VEGF receptor, fit-l and VEGF itself, but further studies are needed to clarify this and the role of another VEGF receptor, flk-I (KDR), in NSCLCs. Rak et al. (30) reported that the expression of a mutant ras oncogene is associated with marked up-regulation of VEGF mRNA and found functional protein to be secreted by human and rodent tumor cell lines expressing mutant K-ras and H-ras oncogenes, respectively. Further, they showed that genetic disruption of mutant K-ras allele in human colon carcinoma cells was
